An IIFL report quotes the management of Strides Shasun as saying that pharmaceutical benefits scheme price cuts have bottomed out. In an interview to CNBC-TV18, Shashank Sinha, MD of the company spoke about the same and gave his outlook for the future.
Sinha said that we are hoping to launch 12-15 new products in next one year.
He further said that under the new Generic Drug User Fee Amendments (GDUFA) regime, abbreviated new drug applications (ANDAs) are approved within a year.
Talking about business, he said we have been investing heavily in the business, especially research and development (R&D).
We are targeting 30-35 product launches on an annual basis in Australia, he added.
For entire interview, watch accompanying video.
Discover the latest Business News, Sensex, and Nifty updates. Obtain Personal Finance insights, tax queries, and expert opinions on Moneycontrol or download the Moneycontrol App to stay updated!
